Mesoblast (MESO) Q3 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21 streetwisereports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetwisereports.com Daily Mail and Mail on Sunday newspapers.
Markets
ADiTx Therapeutics (ADTX)
In a report issued on April 8, Jason Kolbert from Dawson James maintained a Buy rating on ADiTx Therapeutics, with a price target of $14.00. The company’s shares closed last Thursday at $2.56, close to its 52-week low of $1.62.
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -5.3% and a 37.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Sorrento Therapeutics, and Anavex Life Sciences.
ADiTx Therapeutics has an analyst consensus of Moderate Buy.
DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today investorplace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investorplace.com Daily Mail and Mail on Sunday newspapers.
In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: